Home/Pipeline/RASTRUM™ 3D Tumor‑Immune Co‑culture Platform

RASTRUM™ 3D Tumor‑Immune Co‑culture Platform

Immuno‑oncology

Pre‑clinicalActive

Key Facts

Indication
Immuno‑oncology
Phase
Pre‑clinical
Status
Active
Company

About Inventia Life Science

Inventia delivers high‑throughput 3D bioprinting platforms that generate assay‑ready disease models for faster, more predictive drug discovery.

View full company profile

Other Immuno‑oncology Drugs

DrugCompanyPhase
MAV-002Maven BioPreclinical